NCT01390571已完成1 期
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 7
- 主要终点
- Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study
研究概览
简要总结
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more sensitive to the drug.
PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and temozolomide in treating patients with relapsed glioblastoma.
详细描述
OBJECTIVES:
Primary
- To determine whether olaparib crosses the blood-brain barrier (BBB) and achieves tumor penetration in patients with relapsed glioblastoma. (Stage 1)
- To determine the safety and tolerability of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2)
Secondary
- To assess BBB disruption and BBB permeability in patients with relapsed glioblastoma. (Stage 1 and stage 2 maximum-tolerated dose [MTD] expansion cohort)
- To assess the possible anti-tumor activity of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2)
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed grade IV glioblastoma
- •Radiological diagnosis of recurrent or progressive disease according to Response Assessment in Neuro-Oncology Working Group (RANO) criteria, which is suitable for palliative resection
- •Must have an adequate amount of tumor tissue available
- •Previously received first-line treatment with radical radiotherapy, or chemoradiation followed by adjuvant chemotherapy
- •No prior chemotherapy for recurrent disease
- •PATIENT CHARACTERISTICS:
- •WHO performance status 0-2
- •Life expectancy > 12 weeks
- •Hemoglobin ≥ 10.0 g/dL
- •Absolute neutrophil count ≥ 1.5 x 10^9/L
- •Platelet count ≥ 100 x 10^9/L
- •Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
- •ALT or AST ≤ 2.5 times ULN
- •Calculated creatinine clearance ≥ 50 mL/min OR isotope clearance measurement ≥ 50 mL/min (uncorrected)
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use one (male) or two (female) highly effective forms of contraception 4 weeks prior to, during, and for 6 months after completion of study therapy
- •Able to swallow and retain oral medications
- •Not at high medical risk due to non-malignant systemic disease, including active uncontrolled infection
- •No known hepatitis B, hepatitis C, or HIV seropositivity
- •No concurrent congestive heart failure, prior history of NYHA class III-IV cardiac disease, prior history of cardiac ischemia, or prior history of cardiac arrhythmia within the past 12 months
- •No grand mal seizures occurring ≥ 3 times per week over the past month
- •No gastrointestinal disorders likely to interfere with absorption of the study medication
- •No known hypersensitivity to any of the components of olaparib
- •No known hypersensitivity to temozolomide (TMZ) or any of its components, or to dacarbazine (DTIC) (for patients enrolled in stage 2 study only)
- •No known lactose intolerance (for patients enrolled in the stage 2 study only)
- •No metal fragments in the eyes (shrapnel or bullet injuries are excluded on the basis of their unsuitability to undergo MRI scans)
- •No other condition which, in the Investigator's opinion, would not make the patient a good candidate for the clinical trial
排除标准
- •See Disease Characteristics
- •No ongoing toxic manifestations from previous treatments except for alopecia or grade 1 toxicities which, in the opinion of the Investigator and the Drug Development Office (DDO), should not exclude the patient
- •At least 12 weeks since prior radiotherapy, endocrine therapy, or immunotherapy
- •At least 6 weeks since prior major surgery
- •At least 4 weeks since prior chemotherapy
- •At least 4 weeks since prior immunizations with live vaccines (or expected to receive vaccines during the trial and up to at least 6 months after receiving last study treatment), including BCG and yellow fever vaccines
- •No prior PARP inhibitors, including olaparib
- •No prior major thoracic or abdominal surgery from which the patient has not yet recovered
- •No prior heart surgery
- •No pacemakers
- •No change to systemic steroids dose within 5 days prior to enrollment (i.e., must be on a stable dose at time of enrollment and remain on a stable dose throughout the treatment period)
- •No herbal supplements and/or ingestion of foods known to modulate CYP3A4 enzyme activity from time entered on screening period until 28 days after the last dose of study medication
- •No concurrent drugs known to be potent inducers of CYP3A4, including phenytoin, carbamazepine, phenobarbital, rifampicin, rifapentine, rifabutin, nevirapine, modafinil, or St. John wort (wash-out period for phenobarbital is 5 weeks, 3 weeks for all others)
- •No concurrent drugs known to be potent inhibitors of CYP3A4, including ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, or nelfinavir (wash-out period is 1 week)
- •No concurrent or planned participation in another interventional clinical study
- •Participation in an observational study is acceptable
- •No concurrent warfarin (patients requiring anticoagulation should be given subcutaneous low molecular weight heparin)
- •No other concurrent anticancer therapy (including radiotherapy) or investigational drugs
- •No blood transfusions within 4 weeks prior to study start of features suggestive of myelodysplasia or AML
结局指标
主要结局
Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study
Maximum-tolerated dose of olaparib in combination with temozolomide (stage 2)
Toxicity profile and dose-limiting toxicity as assessed by NCI CTCAE Version 4.02 (stage 2)
次要结局
- Measurement of blood-brain barrier (BBB) disruption and permeability biomarkers by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) (stage 1 and stage 2 MTD expansion cohort)
- Progression-free survival at 6 months post-surgery as assessed by the Response Assessment in Neuro-Oncology Working Group (RANO) criteria from conventional MRI and clinical assessment (stage 2)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancerbrca1 Mutation Carrierbrca2 Mutation CarrierBreast CancerOvarian CancerNCT00664781Cancer Research UK78
已完成
1 期
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerStage IIIC Rectal CancerMucinous Adenocarcinoma of the RectumSignet Ring Adenocarcinoma of the ColonMucinous Adenocarcinoma of the ColonStage IIIA Colon CancerStage IIIA Rectal CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the RectumStage IIIB Rectal CancerStage IVB Colon CancerRecurrent Colon CancerStage IVA Rectal CancerStage IVB Rectal CancerStage IIIB Colon CancerStage IIIC Colon CancerStage IVA Colon CancerNCT00060411National Cancer Institute (NCI)24
已完成
1 期
Phase 1 trial of olaparib with temozolomide in relapsed glioblastomaBrain TumourMalignant neoplasm of brainCancerISRCTN47380065Cancer Research UK45
已完成
1 期
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerBreast CancerNCT00755885Cancer Research UK77
已完成
1 期
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerBreast CancerNCT00513058UNICANCER33